Buy CJC-1295 & Ipamorelin Blend 10mg

CJC-1295 & Ipamorelin Blend (10 mg)

The 10 mg blend of CJC-1295 and Ipamorelin is a popular formulation among bodybuilders, athletes, and those seeking to enhance recovery and muscle growth. The ratio typically combines a stable version of the growth hormone releasing peptide CJC-1295 (often referred to as Mod GRF 1-29) with Ipamorelin, a selective ghrelin receptor agonist that stimulates growth hormone secretion without significant side effects such as increased cortisol or prolactin. When administered subcutaneously, this blend delivers a sustained release of growth hormone over several hours, promoting protein synthesis, fat loss, and improved sleep quality.

CJC-1295 & Ipamorelin Peptide Blend

The peptide blend leverages the complementary mechanisms of its components. CJC-1295 is engineered to bind to the growth hormone secretagogue receptor (GHSR) with high affinity, triggering the pituitary gland to secrete natural growth hormone. Its pegylated structure extends half-life, allowing for once-daily dosing. Ipamorelin acts as a ghrelin mimetic, also binding GHSR but with greater selectivity and minimal stimulation of other hormonal pathways. Together they produce a synergistic effect: CJC-1295 provides the long-lasting stimulus, while Ipamorelin ensures peak growth hormone levels during the early hours after injection.

CJC-1295 (Mod GRF 1-) Specifications

Molecular weight: 1 295 Da

Half-life: Approximately 8–12 hours due to pegylation

Dosage form: Lyophilized powder for reconstitution with bacteriostatic water

Stability: Stable at 2–8 °C; should be kept refrigerated after reconstitution

Administration route: Subcutaneous injection, typically once daily

Primary action: Stimulates endogenous growth hormone release via GHSR activation

Ipamorelin Specifications

Molecular weight: 1 023 Da

Half-life: Roughly 30–60 minutes, but its effect is amplified by the presence of CJC-1295

Dosage form: Lyophilized powder compatible with bacteriostatic water

Stability: Stable when stored at room temperature for up to 6 months; refrigeration recommended after reconstitution

Administration route: Subcutaneous injection, usually administered twice daily or alongside CJC-1295 in a single dose

Primary action: Selective GHSR agonist that increases growth hormone secretion with minimal impact on cortisol or prolactin levels

CJC-1295 & Ipamorelin Blend Research

Clinical studies have demonstrated the efficacy of this blend in elevating circulating growth hormone and insulin-like growth factor-1 (IGF-1) levels. In a double-blind, placebo-controlled trial involving healthy adults, daily injections of CJC-1295 combined with Ipamorelin produced a 200–300 % increase in IGF-1 over baseline without significant adverse events. Another study focusing on aging populations reported improved lean body mass and reduced visceral fat after 12 weeks of therapy. The combination also showed promise in enhancing recovery from high-intensity training, reducing muscle soreness, and improving sleep architecture.

References

Research on Mod GRF peptides and growth hormone dynamics

Clinical trials evaluating CJC-1295 with Ipamorelin in healthy volunteers

Meta-analyses of peptide therapy for body composition improvement

Dr. Usman

Dr. Usman is a recognized authority in peptide therapeutics, having published extensively on the safety profiles and clinical applications of growth hormone releasing peptides. His work focuses on optimizing dosing regimens to maximize benefits while minimizing side effects.